\-\ Texto\\:\\ \ \(0\)\
\-\ bilateral\\ leg\\ weakness\\ and\\ absent\\ reflexes\\.\ \(0\)\
\-\ chemotherapy\\ and\\ radiation\\.\ \(3\)\
\-\ infiltrative\\ intramedullary\\ lesion\\ extending\\ from\\ t3\\ to\\ the\\ conus\\.\\ \\ the\\ mass\\ demonstrates\\ irregular\\ enhancement\\ after\\ contrast\\ administration\\.\ \(0\)\
\-\ spinal\\ cord\\ astrocytoma\\,\\ malignant\ \(0\)\
\-\ astrocytoma\ \(206\)\
\-\ ependymoma\ \(74\)\
\-\ hemangioblastoma\ \(37\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ 12\\ year\\ old\\ girl\\ with\\ progressive\\ back\\ pain\\ and\\ leg\\ weakness\\ over\\ the\\ past\\ 3\\ months\\.\\ \\ no\\ urinary\\ or\\ rectal\\ incontinence\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ leg\\:\\ 0\\.2837899587943288\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.2837899587943288\ \(0\)\
\-\ weakness\\:\\ 0\\.27435940695464034\ \(0\)\
\-\ intramedullary\\:\\ 0\\.20628201459104928\ \(0\)\
\-\ t3\\:\\ 0\\.20357220999140427\ \(0\)\
\-\ conus\\:\\ 0\\.20188205897816208\ \(0\)\
\-\ incontinence\\:\\ 0\\.19874151987081876\ \(0\)\
\-\ infiltrative\\:\\ 0\\.19260931564713768\ \(0\)\
\-\ rectal\\:\\ 0\\.19021184249140408\ \(0\)\
\-\ hemangioblastoma\\:\\ 0\\.1879770390674599\ \(0\)\
\-\ reflexes\\:\\ 0\\.16433687824356036\ \(0\)\
\-\ urinary\\:\\ 0\\.16254145327296318\ \(0\)\
\-\ ependymoma\\:\\ 0\\.15877154975482624\ \(0\)\
\-\ absent\\:\\ 0\\.1542050358060501\ \(0\)\
\-\ administration\\:\\ 0\\.14968415998177734\ \(0\)\
\-\ irregular\\:\\ 0\\.1451156581158564\ \(0\)\
\-\ progressive\\:\\ 0\\.1439593738404323\ \(0\)\
\-\ cord\\:\\ 0\\.1393294256867615\ \(0\)\
\-\ malignant\\:\\ 0\\.13398665325029963\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.1334660939147158\ \(0\)\
\-\ spinal\\:\\ 0\\.1334660939147158\ \(0\)\
\-\ girl\\:\\ 0\\.13185350446091962\ \(0\)\
\-\ 12\\:\\ 0\\.12849017396645884\ \(0\)\
\-\ extending\\:\\ 0\\.12744125609630474\ \(0\)\
\-\ back\\:\\ 0\\.12535771002656773\ \(0\)\
\-\ radiation\\:\\ 0\\.1245598327721217\ \(0\)\
\-\ past\\:\\ 0\\.12234959194389106\ \(0\)\
\-\ and\\:\\ 0\\.11652069597600712\ \(0\)\
\-\ the\\:\\ 0\\.11251622776300106\ \(0\)\
\-\ months\\:\\ 0\\.10940961457427267\ \(0\)\
\-\ enhancement\\:\\ 0\\.10818817300105442\ \(0\)\
\-\ over\\:\\ 0\\.10451563590511363\ \(0\)\
\-\ metastatic\\:\\ 0\\.10308824776651254\ \(0\)\
\-\ bilateral\\:\\ 0\\.10101819828892569\ \(0\)\
\-\ demonstrates\\:\\ 0\\.09443051686106776\ \(0\)\
\-\ contrast\\:\\ 0\\.09132733522234986\ \(0\)\
\-\ after\\:\\ 0\\.09118388388292042\ \(0\)\
\-\ lesion\\:\\ 0\\.09011359544740956\ \(0\)\
\-\ disease\\:\\ 0\\.07890014784090794\ \(0\)\
\-\ from\\:\\ 0\\.07465089494305326\ \(0\)\
\-\ mass\\:\\ 0\\.07179680995517591\ \(0\)\
\-\ pain\\:\\ 0\\.0672600427775091\ \(0\)\
\-\ or\\:\\ 0\\.06538894585036664\ \(0\)\
\-\ no\\:\\ 0\\.06112339618870437\ \(0\)\
\-\ year\\:\\ 0\\.05792646499984793\ \(0\)\
\-\ old\\:\\ 0\\.05562945814332931\ \(0\)\
\-\ to\\:\\ 0\\.04699035569766956\ \(0\)\
\-\ with\\:\\ 0\\.03680548563571924\ \(0\)\
